BM

Bryan M. Reasons

Former Executive Vice President and CFO

Mallinckrodt Pharmaceuticals

Roles

Former Executive Vice President and CFOatMallinckrodt Pharmaceuticals
Chief Financial OfficeratADMA Biologics

Mallinckrodt Pharmaceuticals Pipeline

DrugIndicationPhase
Terlipressin (TERLIVAZ®)Hepatorenal Syndrome Type 1 (HRS-1)Approved
Stannsoporfin (INH-001)Prevention of severe hyperbilirubinemia in newbornsPhase 3
StrataGraftThermal BurnsApproved
H.P. Acthar® GelMultiple autoimmune/inflammatory conditionsApproved